Changes and significance of YKL-40 after thrombolytic therapy for acute myocardial infarction

Objective: To investigate the changes and its significance caused by serum enzyme chitin 40(YKL-40) after thrombolytic therapy for non-ST-segment elevation myocardial infarction and ST-segment elevation myocardial infarction.Methods: The serum YKL-40 levels of 17 patients with ST-segment elevation myocardial infarction before and after thrombolytic treatment,18 patients with non-ST-segment elevation myocardial infarction and 20 healthy people without any detected heart related diseases were detected.The patients with ST-segment elevation myocardial infarction before thrombolytic treatment was compared to patients with non-ST-segment elevation myocardial infarction,healthy people and patients with ST-segment elevation myocardial infarction after thrombolytic treatment.Results: The serum YKL-40 level of patients with ST-segment elevation myocardial infarction before thrombolytic treatment was [(157.56±52.35) μg/L(75.02-558.04 μg/L)],which was significantly higher than [(97.3±36.04) μg/L(53.2-199.05 μg/L)] of healthy people(P0.05) and [(124.30±41.12) μg/L(67.5-224.8 μg/L)] of patients with non-ST-segment elevation myocardial infarction(P0.05).The YKL-40 levels between healthy people and patients with non-ST-segment elevation myocardial infarction were statistically significant(P0.05).The YKL-40 level after thrombolytic therapy was [(106.45±39.22) μg/L(64.13-159.24 μg/L),which was significantly different from that before thrombolytic therapy(P0.05),but was no significantly different compared with the health group(P0.05).Conclusion: Early diagnosis of serum YKL-40 levels in the patients with acute myocardial infarction has important clinical value in therapeutic effects.